Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergen sublingual tablet
- Development stage
- Unknown
- Lead developer
- Green Immunology
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
House dust mite allergen sublingual tablet is an allergen immunotherapy (AIT) product being developed by Green Immunology Co., Ltd. for the treatment of allergic rhinitis and allergic conjunctivitis caused by house dust mite (HDM) sensitivity. The tablet contains standardized extracts of HDM allergens, typically from *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*. The therapeutic approach, known as sublingual immunotherapy (SLIT), involves placing the tablet under the tongue to induce immunological tolerance. This process works by shifting the immune response from a pro-allergic Th2 profile toward a regulatory T-cell (Treg) and Th1 profile, leading to the production of allergen-specific IgG4 antibodies that block IgE-mediated allergic reactions. Green Immunology is currently evaluating the safety, tolerability, and immunologic effects of this formulation in clinical trials in China.
- Other names
- house dust mite allergen sublingual tabletHDM SLIT tablet
02
Targets
House dust mite allergen proteins (Dermatophagoides farinae and Dermatophagoides pteronyssinus)
Beyond the preview
Go deeper on house dust mite allergen sublingual tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergen sublingual tablet.